Ace Therapeutics Highlights In Vivo Pharmacodynamic Evaluation Services to Advance Cardiovascular Drug Development
New York, United States – November 11, 2026 – Ace Therapeutics, a contract research organization specializing in preclinical drug research for cardiovascular diseases, is highlighting its comprehensive services for in vivo cardiovascular drug evaluation, designed to help clients obtain critical pharmacodynamic data for candidate therapies.
Ace Therapeutics’ platform addresses a pivotal stage in the development pipeline by offering integrated solutions for preclinical cardiovascular pharmacodynamic studies. These services are developed to help researchers determine effective dose ranges and identify reliable pharmacodynamic indicators before advancing to later stages of development.
Because pharmacological responses to cardiovascular drugs can differ markedly between species, selecting appropriate animal models is a key consideration in in vivo cardiovascular pharmacodynamic studies. Ace Therapeutics provides guidance on model selection based on physiological similarity, genetic and molecular homology, and reproducibility, helping to keep study results consistent and translatable. With a wide range of animal models of cardiovascular diseases, including models of atherosclerosis, heart failure, hypertension, and hypertrophic cardiomyopathy, among others, clients can select appropriate disease models according to their research projects. Additionally, Ace Therapeutics assists with the design of dosage regimens, drawing on in vitro data, reference compounds, and pre-test results to establish appropriate dosing schedules.
Typically, pharmacodynamic evaluation of cardiovascular drugs involves monitoring hemodynamic parameters such as heart rate, blood pressure, cardiac output, and vascular resistance, alongside the analysis of relevant cardiovascular biomarkers to support assessment of the desired pharmacodynamic effect. Additionally, the studies often incorporate mechanistic investigations to identify receptor-binding targets and signaling pathway effects, providing a more complete picture of a drug’s action. These integrated outputs generated from preclinical cardiovascular pharmacodynamic studies help drug developers make evidence‑based go‑or‑no‑go decisions for subsequent development stages.
Ace Therapeutics positions these capabilities as part of a broader commitment to preclinical cardiovascular drug research, offering clients end-to-end support from animal model selection through to final data reporting.
About Ace Therapeutics
Ace Therapeutics is a contract research organization dedicated to advancing cardiovascular disease research through comprehensive preclinical solutions. It provides cardiovascular disease model development services, biomarker assay services, and biospecimen collection and analysis services for basic research and drug development across a wide spectrum of cardiovascular conditions.
Media Contact
Company Name: Ace Therapeutics
Contact Person: Daisy Mostert
Email: Send Email
Phone: 1 516 441 0167
Country: United States
Website: https://www.acetherapeutics.com/
